Please ensure Javascript is enabled for purposes of website accessibility

CASI Pharmaceuticals launches first commercial product (access required)

Rockville-based CASI Pharmaceuticals Inc.  announced Monday the launch of Evomela, its first commercial product for the company. Evomela, developed as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, was released in China after receiving market approval by the China National Medical Products Administration (NMPA). It is the only approved ...

To purchase a reprint of this article, contact [email protected].